Altimmune to Announce Third Quarter 2019 Financial Results on November 14
GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial results for the three and nine months ended September 30, 2019 before the market opens and host a conference call on Thursday, November 14, 2019.
Conference Call Details Date: Thursday, November 14 Time: 8:30 am Eastern Time Domestic: 855-327-6837 International: 631-891-4304 Conference ID: 10008064 Webcast: http://public.viavid.com/index.php?id=136942
About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcellTM), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAXTM and NasoShieldTM). For more information on Altimmune, please visit www.altimmune.com.
Contacts: Will Brown Ashley R. Robinson Chief Financial Officer LifeSci Advisors, LLC Phone: 240-654-1450 617-775-5956 firstname.lastname@example.org email@example.com